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High time to use rapid tests to detect multidrug resistance  
in sputum smear-negative tuberculosis in Belarus
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K. Tayler-Smith,5 M. Dara,4 R. Zachariah5
Eastern Europe is facing an epidemic of multi-drug-resistant tuberculosis (MDR-TB).1,2 Belarus is 
one of the 27 high MDR-TB burden countries desig-
nated by the World Health Organization (WHO). A 
countrywide survey conducted in 2011 in Belarus re-
vealed a prevalence of MDR-TB of 32% among new 
and 76% among previously treated TB cases, the high-
est documented rates worldwide.3,4 However, these 
levels were found among sputum smear-positive pul-
monary TB (SP-PTB) patients. The levels of MDR-TB 
among smear-negative pulmonary TB (SN-PTB) pa-
tients are unknown, and this group accounts for 63% 
of all notified new pulmonary TB cases in Belarus.1
Countries in the WHO European region endorsed 
the ‘Consolidated Action Plan, 2011–2015’, with the 
aim of detecting 85% of estimated MDR-TB cases and 
successfully treating at least 75% of these by 2015.5 
Achieving these objectives will not be possible without 
appropriate management of MDR-TB among SN-PTB.
In Belarus, all TB patients have universal access to 
culture and drug susceptibility testing (CDST). In 
2012, at the start of the countrywide roll-out of rapid 
molecular diagnostics (such as Xpert® MTB/RIF [Ce-
pheid, Inc, Sunnyvale, CA, USA] and line probe as-
says), national policy prioritised their use for 
smear-positive TB patients, while SN-PTB patients 
were investigated using conventional methods, often 
delaying the diagnosis of MDR-TB by 2–4 months. 
While awaiting the results, SN-PTB patients were ini-
tiated on a first-line drug regimen, which was obvi-
ously inadequate if they harboured MDR-TB bacilli. 
With the increasing availability of rapid molecular 
diagnostics, the country is currently aiming at uni-
versal coverage of all presumptive TB cases with mo-
lecular testing. Despite the national policy, SN-PTB 
patients do not receive the same priority as 
smear-positive TB patients, as they are traditionally 
perceived to be less infectious and clinically less se-
vere. Currently, there is no published information 
from Belarus or similar settings in Eastern Europe on 
the proportion of SN-PTB patients with MDR-TB. 
Such information provides the evidence required to 
decide on and justify the use of rapid molecular diag-
nostics for all SN-PTB patients.
In this countrywide audit in Belarus, we therefore 
aimed to assess the proportion of MDR-TB among SN-
PTB patients registered in 2012 and the associated de-
mographic and clinical factors.
METHODS
Study design
This was a retrospective cohort study using data rou-
tinely recorded in the national electronic TB register.
Setting
Belarus has a population of 9.5 million, with 72% liv-
ing in urban areas. There are six administrative re-
gions (Brest, Gomel, Grodno, Mogilev, Minsk and 
Vitebsk) and 121 districts. The Ministry of Health 
(MOH) oversees the implementation of TB control ac-
tivities in the country. The Republican Scientific and 
Practical Centre for Pulmonology and Tuberculosis 
(RSPCPT) in Minsk is the central National Tuberculosis 
Programme (NTP) unit responsible for the develop-
ment and implementation of TB policies. The Minis-
try of the Interior has a parallel health care system for 
managing TB patients in prisons, and reports to the 
NTP. Belarus follows the WHO-recommended Stop TB 
Strategy, and anti-tuberculosis control interventions 
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Setting: Belarus (Eastern Europe) is facing an epidemic 
of multidrug-resistant tuberculosis (MDR-TB). In 2012, 
rapid molecular diagnostics were prioritised for sputum 
smear-positive pulmonary tuberculosis (PTB) patients to 
diagnose MDR-TB, while pulmonary sputum smear-nega-
tive pulmonary TB (SN-PTB) patients were investigated 
using conventional methods, often delaying the diagno-
sis of MDR-TB by 2–4 months.
Objective: To determine the proportion of MDR-TB 
among SN-PTB patients registered in 2012 and associ-
ated clinical and demographic factors.
Design: Retrospective cohort study using countrywide 
data from the national electronic TB register.
Results: Of the 5377 TB cases registered, 2960 (55%) 
were SN-PTB. Of the latter, 1639 (55%) were culture-pos-
itive, of whom 768 (47%) had MDR-TB: 33% (363/1084) 
were new and 73% (405/555) previously treated pa-
tients. Previous history of treatment, age, region, urban 
residence, human immunodeficiency virus (HIV) status 
and being a pensioner were independently associated 
with MDR-TB.
Conclusion: About half of culture-positive SN-PTB pa-
tients have MDR-TB and this rises to over 7/10 for retreat-
ment cases. A national policy decision to extend rapid 
molecular diagnostics universally to all PTB patients, in-
cluding SN-PTB, seems justified. Steps need to be taken 
to ensure implementation of this urgent priority, given 
the patient and public health implications of delayed 
diagnosis.
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are delivered through a network of dedicated TB facili-
ties and primary health care services.
In addition to the paper-based TB and MDR-TB reg-
isters, Belarus has implemented a national web-based 
individualised electronic register of all TB patients (in-
cluding the penitentiary system) since 2009 and 
MDR-TB patients since 2011. The data for all TB and 
MDR-TB patients are entered via the web from six re-
gional TB facilities — the regional monitoring and 
evaluation (M&E) units and the Republican TB Prison 
Hospital. These data are validated on main programme 
indicators by the central M&E unit located at the RSP-
CPT. Recording and reporting of case definitions and 
treatment outcomes follow WHO guidelines, and all 
patient-based information is captured in the national 
electronic TB register.
Diagnosis of smear-negative pulmonary 
tuberculosis patients
The case-finding strategy in Belarus involves an active 
and a passive strategy. The passive approach involves 
investigating individuals with presumptive TB who 
present to the health care facilities, while the active ap-
proach involves mass annual general population screen-
ing for TB with chest X-ray (fluorography). Coverage 
rates for the latter are more than 80% among the adult 
population.4 Those with symptoms suggestive of TB or 
X-ray findings suggestive of TB are investigated further 
using sputum-smear microscopy with Ziehl-Neelsen 
staining and CDST on solid medium (egg-based 
Löwenstein-Jensen) or liquid medium (BACTEC™ 
MGIT 960 culture; BD Microbiology Systems, Sparks, 
MD).6,7 For all strains resistant to rifampicin (RMP), 
second-line drug susceptibility testing is routinely per-
formed. Patients with at least two sputum smears neg-
ative for acid-fast bacilli and clinical and radiological 
features suggestive of TB are diagnosed as SN-PTB by a 
panel of TB specialists at regional level and initiated 
on first-line treatment while awaiting the results of 
CDST.8 If they are confirmed to have MDR-TB, first-
line treatment is stopped, treatment outcome is de-
clared as ‘failure, primary MDR-TB’ in the TB register 
and the patient is newly registered in the MDR-TB reg-
ister. These patients are removed from the cohort of 
SN-PTB patients for cohort reporting of treatment out-
comes, and are reported as part of the MDR-TB patient 
cohort. All detected MDR-TB patients have access to 
second-line anti-tuberculosis treatment as per national 
guidelines in line with WHO recommendations.3,4,8 
Treatment for MDR-TB is initiated by the board of TB 
specialists. All diagnostic and treatment services are 
provided free of charge.
Definition of multidrug-resistant tuberculosis
Patients with Mycobacterium tuberculosis showing in vi-
tro resistance to at least isoniazid and RMP are consid-
ered to have MDR-TB. In addition, close contacts of 
MDR-TB patients diagnosed with TB are also considered 
as having MDR-TB, irrespective of the laboratory results.
Study population and study period
All SN-PTB patients (adults and children) diagnosed 
and registered in the national electronic TB register of 
Belarus from 1 January to 31 December 2012 were in-
cluded in the study. The study was conducted between 
July 2013 and March 2014.
Data variables and data source
Variables relating to the study objectives were ex-
tracted from the national electronic database and in-
cluded age, sex, previous treatment history, case-find-
ing approach used for diagnosis, site of treatment 
(civilian versus penitentiary sector), HIV status, culture 
(positive or negative) and CDST results (MDR-TB or 
not), date of registration in TB register and date of di-
agnosis of MDR-TB.
Data analysis
Data were analysed using EpiData analysis software, 
version 2.2.2.182 (EpiData Association, Odense, Den-
mark) and STATA version 12.1 (Stata Corporation, Col-
lege Station, TX, USA). Associations between demo-
graphic and clinical factors and MDR-TB were assessed 
using odds ratios (OR) and 95% confidence intervals 
(CI). The χ2 test was used to compare proportions, and 
the level of significance was set at P  0.05. Multivari-
ate analysis using logistic regression was conducted to 
assess the factors independently associated with 
MDR-TB.
Ethics
Ethics approval was obtained from the ethics commit-
tees of the RSPCPT, Minsk, Belarus; Médecins Sans 
Frontières, Geneva, Switzerland; and the International 
Union Against Tuberculosis and Lung Disease, Paris, 
France.
RESULTS
Demographic and clinical characteristics of the 
study population
Of 5377 registered TB patients (after excluding trans-
fer-in cases), 4868 (91%) had pulmonary TB; 2960 
(55%) of these were SN-PTB: 2115 (70%) were males, 
the median age was 43 years (interquartile range [IQR] 
33–53) and 1813 (61%) came from urban areas. About 
half of all patients were from the Gomel and Minsk re-
gions, and Minsk city. Nearly half (1347, 46%) were 
unemployed. HIV status was reported in only 551 pa-
tients (19%) and 111/551 (20%) patients tested were 
HIV-positive. About 4% of the patients were treated in 
the penitentiary sector and 2338 (79%) were detected 
as part of an active case-finding approach.
Smear-negative pulmonary tuberculosis with 
multidrug resistance
Of 2960 SN-PTB patients, 1639 (55%) were culture-pos-
itive. Of the latter, 768 (47%) had MDR-TB: 33% 
(363/1084) among new and 73% (405/555) among 
previously treated patients. When all SN-PTB patients 
(including culture-negative) were used as the denomi-
nator, the proportion of MDR-TB was 27% — 16% of 
new patients and 63% of previously treated patients 
(Figure). The proportion of MDR-TB among cul-
ture-positive SN-PTB patients, stratified by demo-
graphic and clinical characteristics, is shown in Table 
1. On multivariate analysis, previous history of treat-
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ment, age, region, residence, HIV status and being a pensioner 
were independently associated with MDR-TB. A similar analysis 
was carried out for new and previously treated cases separately 
(Table 2). There were no major changes in the directionality or 
magnitude of the associations, although some factors initially 
found to be statistically significant became insignificant due to 
smaller numbers.
Of 768 MDR-TB patients, information on treatment initiation 
was recorded for 660 (86%). Of these, 637 (97%) were started on 
treatment. As there were errors and inconsistencies in recording 
the date of TB registration, MDR-TB diagnosis and treatment initi-
ation, we could not reliably assess the median delays between di-
agnosis and treatment initiation.
DISCUSSION
This is the first study from Belarus showing that nearly one third 
of new patients and three quarters of previously treated patients 
with culture-positive SN-PTB had MDR-TB. This confirms that the 
prevalence of MDR-TB among SN-PTB in the country is as high as 
that among SP-PTB patients.3 While certain factors were associ-
ated with higher or lower likelihood of having MDR-TB, the prev-
alence remained consistently high, at around 40–50%, across the 
different regions and the various socio-demographic and clinical 
subgroups. Of concern is that all SN-PTB patients with MDR-TB 
were treated with first-line treatment regimens while awaiting the 
results of CDST by traditional methods. This might have involved 
delays of up to 3 months, given the turnaround time with con-
ventional CDST methods. From a patient and public health per-
spective, this is tantamount to treatment with ineffective first-line 
drugs, with the concomitant potential risk of amplifying and 
spreading drug-resistant TB in the community.
There are a number of policy and practice implications. First, 
there is an urgent need to increase the availability and use of 
rapid molecular diagnostics for all TB patients from whom bio-
logical samples may be obtained. The way forward is for the 
health authorities to ensure access to rapid molecular diagnostic 
tests such as Xpert in all settings, either by purchasing new 
equipment or by arranging transport of samples. Two issues are 
of global concern with respect to the scale-up of rapid tests for 
diagnosing RMP resistance.9 One relates to low positive predic-
tive value (PPV) in areas of low MDR-TB prevalence, which is 
not applicable to Belarus, a country with high prevalence. Fur-
ther, recent evidence indicates that the Xpert test is more spe-
cific than previously estimated, thus allaying fears of low PPV, 
even in areas of low MDR-TB prevalence.10–13 The second relates 
to a lack of capacity of NTPs to cope with the increased demand 
for treatment as a result of the considerable increase in numbers 
of diagnosed cases. This is also not of concern, as the NTP in Be-
larus has sufficient capacity to treat all diagnosed MDR-TB 
patients.
The high proportion of MDR-TB found among SN-PTB patients 
articulates a call to the NTP to extend the use of molecular diag-
nostic tests to include all those with SN-PTB. From the patient’s 
perspective, such action is likely to foster the institution of 
prompt diagnosis and early initiation on appropriate treatment, 
both of which should favourably impact treatment outcomes.
Considering the increasing availability of Xpert in the country, 
the relatively modest numbers of additional tests (~3000 annually 
in Belarus) that will need to be performed and the limited re-
source implications (~US$36 000, at US$12.00 per test), this rec-
ommendation seems feasible. This notwithstanding, if for any 
reason not all SN-PTB patients can be offered rapid diagnostic 
tests for MDR-TB right away, then the urgent priority would be to 
target the following SN-PTB risk groups: all previously treated pa-
tients (particularly relapse and treatment after failure cases), those 
aged 45 years, living in urban areas or living in Vitebsk or 
Grodno regions. This is, however, a much less preferred option.
Second, we found several factors associated with MDR-TB, the 
strongest being previous history of treatment. Previously treated 
patients had a nearly six times higher risk of MDR-TB than those 
with newly diagnosed TB, and this would seem logical as they 
have already been exposed to first-line anti-tuberculosis regimens 
in the past. Given that nearly three quarters of previously treated 
patients had MDR-TB, a logical option (while waiting for rapid di-
agnostics) would be to start second-line treatment empirically for 
patients with a high clinical probability of active MDR-TB, as per 
the WHO treatment guidelines.14 Based on the results of the 
CDST, treatment may be modified accordingly. This may be life-
saving in certain seriously ill patients, including HIV-positive 
individuals.
Third, the study revealed gaps in the recording of a number of 
variables such as HIV status, drug resistance patterns, dates of TB 
and MDR-TB diagnosis and registrations. Notable was HIV status, 
with 81% not having their status recorded. Considering the previ-
FIGURE Proportion of MDR-TB among smear-negative pulmonary 
tuberculosis patients in Belarus, 2012. *Of these, 17 patients were 
contacts of confirmed MDR-TB patients and were thus treated with 
MDR-TB regimens. TB = tuberculosis; SN-PTB = sputum smear-nega-
tive pulmonary tuberculosis; MDR-TB = multidrug-resistant tubercu-
losis; LTFU = loss to follow-up.
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ously documented strong associations of MDR-TB with HIV-posi-
tive patients3,15 and unfavourable outcomes,16,17,5 this missing in-
formation is of operational and clinical significance. The reasons 
for this shortcoming were not known, but the programme has al-
ready identified this gap and steps are being taken to increase the 
uptake of HIV testing and improve its recording in the TB 
registers.
There were several strengths to our study. First, this was a 
countrywide study which included all SN-PTB patients registered 
in 2012, and is thus representative of the situation in Belarus. Sec-
ond, this is the first time globally that a study has reported on the 
prevalence of MDR-TB among SN-PTB patients. The study also 
met the requirements of the Strengthening the Reporting of Ob-
servational Studies in Epidemiology (STROBE) guidelines, includ-
ing ethics.18,19
There were also some study limitations, mainly related to the 
operational nature of the study and reliance on data routinely 
recorded by the NTP. First, there were recording errors, includ-
ing missing values and some inconsistencies across the vari-
ables, especially HIV and dates of TB and MDR-TB registrations. 
In this study, we could not assess the proportion of MDR-TB 
among extra-pulmonary TB patients, which could be a topic for 
future research. In addition, we could not analyse the drug re-
sistance patterns, including that of second-line drugs. This in-
formation could have been valuable to the NTP for assessing 
whether or not the current first- and second-line treatment regi-
mens are adequate in the context of an MDR-TB epidemic. 
From the programme perspective, this is an important finding, 
and additional efforts are needed to improve the quality of data 
collection, which includes staff training in the regions and en-
hancing supervision and data validation on key indicators at 
central NTP level. On the other hand, as rapid molecular diag-
nostic testing can detect any biological material, even dead ba-
cilli, and the radiological evidence alone may not be indicative 
TABLE 1 Prevalence of MDR-TB among all sputum smear-negative, culture-positive pulmonary TB patients in Belarus, 2012
Characteristic
Total
n
MDR-TB at baseline
n (%) Crude OR (95%CI) Adjusted OR (95%CI)
Total 1639 768 (47)
Age, years*
 45 854 434 (50) 1 1
 45 784 333 (42) 0.7 (0.6–0.9)† 0.7 (0.6–0.9)†
Sex
 Female 385 161 (42) 1 1
 Male 1254 607 (48) 1.3 (1.0–1.6)† 1.1 (0.8–1.4)
Administrative region
 Brest region 180 73 (41) 1 1
 Vitebsk region 157 79 (50) 1.5 (0.9–2.3) 2.1 (1.3–3.3)†
 Gomel region 295 125 (42) 1.1 (0.7–1.6) 1.1 (0.7–1.7)
 Grodno region 244 127 (52) 1.6 (1.1–2.3)† 1.9 (1.2–2.9)†
 Minsk region 309 168 (54) 1.7 (1.2–2.5) 1.0 (0.6–1.7)
 Minsk city 181 78 (43) 1.1 (0.7–1.7)† 0.9 (0.6–1.5)
 Mogilev region 270 116 (43) 1.1 (0.8–1.6) 1.4 (0.9–2.1)
 Other countries 3 2 (67) 2.9 (0.3–32.9) 4.2 (0.4–49.6)
Residence
 Urban 969 478 (49) 1 1
 Rural 670 290 (43) 0.8 (0.6–0.9)† 0.7 (0.6–0.9)†
Occupation
 Employed 586 284 (48) 1 1
 Pensioner 186 56 (30) 0.5 (0.3–0.7)† 0.6 (0.4–0.9)†
 Unemployed 833 410 (49) 1.0 (0.8–1.3) 0.9 (0.7–1.2)
 Student 34 18 (53) 1.2 (0.6–2.4) 1.2 (0.6–2.5)
HIV status
 Negative 282 166 (59) 1 1
 Positive 64 36 (56) 0.9 (0.5–1.6) 0.7 (0.4–1.4)
 Unknown 1293 566 (44) 0.5 (0.4–0.7† 0.4 (0.3–0.6)†
Civil vs. penitentiary
 Penitentiary 61 28 (46) 1 –
 Civil sector 1578 740 (47) 1.0 (0.6–1.7)
Case finding
 Active 1288 613 (48) 1 –
 Passive 351 155 (44) 0.9 (0.7–1.1)
Category
 New cases 1084 363 (33) 1 1
 Previously treated 555 405 (73) 5.4 (4.2–6.7)† 5.9 (4.6–7.5)†
* Not recorded for one patient.
† Statistically significant (P  0.05).
MDR-TB = multidrug-resistant tuberculosis; OR = odds ratio; CI = confidence interval; HIV = human immunodeficiency virus.
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of active TB, diagnosis of active MDR-TB among sputum 
smear-negative patients needs to be carefully balanced against 
clinical evidence.
In conclusion, this study showed that the prevalence of 
MDR-TB among culture-positive SN-PTB patients was as high as 
among SP-PTB patients in Belarus, and makes a strong case for a 
national policy decision to extend rapid diagnostics to all SN-PTB 
patients in the country. Anything short of that would mean 
sub-standard care with potentially serious patient and public 
health implications.
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TABLE 2 Risk factors for MDR-TB among sputum smear-negative, 
culture-positive pulmonary TB patients in Belarus, stratified by new 
and previously treated cases, 2012
Characteristic
New cases
aOR (95%CI)
Previously treated cases
aOR (95%CI)
Total 1084 555
Age, years*
 45 1 1
 45 0.8 (0.6–1.0) 0.6 (0.4–0.9)†
Sex
 Female 1 1
 Male 1.0 (0.8–1.5) 1.0 (0.6–1.9)
Administrative region
 Brest region 1 1
 Vitebsk region 2.0 (1.1–3.5)† 2.0 (0.8–5.0)
 Gomel region 0.9 (0.5–1.5) 1.5 (0.7–3.2)
 Grodno region 1.7 (1.0–2.9)† 2.1 (1.0–4.7)†
 Minsk region 0.8 (0.4–1.5) 1.4 (0.7–3.0)
 Minsk city 0.9 (0.5–1.6) 0.9 (0.4–2.1)
 Mogilev region 1.6 (0.9–2.6) 0.9 (0.4–2.0)
 Other counties 3.6 (0.3–43.6) –
Residence
 Urban 1 1
 Rural 0.7 (0.5–0.9)† 0.7 (0.5–1.0)†
Occupation
 Employed 1 1
 Pensioner 0.8 (0.5–1.3) 0.3 (0.1–0.6)†
 Unemployed 1.0 (0.8–1.4) 0.7 (0.4–1.1)
 Student 1.0 (0.4–2.3) –
HIV status
 Negative 1 1
 Positive 0.8 (0.4–1.6) 0.8 (0.1–4.2)
 Unknown 0.4 (0.2–0.7)† 0.3 (0.2–0.7)†
* Not recorded for one patient.
† Statistically significant (P  0.05).
MDR-TB = multi-drug resistant tuberculosis; aOR = adjusted odds ratio; CI = confi-
dence interval.
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Contexte  :  Le Belarus (Europe de l’Est) est confronté à une épidémie 
de tuberculose multirésistante (TB-MDR). En 2012, les patients 
atteints de tuberculose pulmonaire (TBP) à frottis positif ont bénéficié 
en priorité de diagnostics moléculaires pour confirmer une TB-MDR, 
tandis que les patients atteints de TBP à frottis négatif (SN-PTB) ont 
bénéficié de méthodes conventionnelles qui retardaient souvent le 
diagnostic de TB-MDR de 2 à 4 mois.
Objectif  :  Déterminer la proportion de TB-MDR parmi les patients 
SN-PTB enregistrés en 2012, ainsi que les facteurs cliniques et 
démographiques associés.
Schéma  :  Etude de cohorte rétrospective basée sur des données 
émanant de tout le pays grâce au registre électronique national de la 
TB.
Résultats  :  Sur 5377 cas de TB enregistrés, 2960 (55%) étaient des 
SN-PTB. Parmi ces derniers, 1639 (55%) avaient une culture positive, 
dont 768 (47%) avaient une TB-MDR : 33% (363/1084) nouveaux 
cas et 73% (405/555) patients déjà traités préalablement. La notion 
de traitement antérieur, l’âge, la région, la résidence en milieu urbain, 
le statut à l’égard du virus de l’immunodéficience humaine et le fait 
d’être retraité étaient indépendamment associés à la TB-MDR.
Conclusion  :  Près de la moitié des patients SN-PTB à culture 
positive ont une TB-MDR, et dans les cas de retraitement, on arrive 
à plus de sept patients sur dix. La décision politique nationale 
d’extension des diagnostics moléculaires rapides à tous les patients 
TBP, y compris les patients SN-PTB, semble donc justifiée. Il est 
nécessaire de prendre des mesures afin d’assurer la mise en œuvre 
de cette priorité urgente, en raison des implications d’un 
diagnostic retardé à la fois pour les patients et en termes de santé 
publique.  
Marco de referencia: El país de Bielorrusia, en Europa oriental, 
afronta una epidemia de tuberculosis multidrogorresistente (TB-
MDR). En el 2012, se privilegió la práctica de las pruebas moleculares 
rápidas con el fin de diagnosticar la TB-MDR en los pacientes con TB 
pulmonar (TBP) y baciloscopia positiva y los casos con baciloscopia 
negativa (SN-PTB) se investigaron mediante los métodos clásicos, lo 
cual solía retardar de dos a cuatro meses el diagnóstico de la 
TB-MDR.
Objetivo: Determinar en los pacientes SN-PTB registrados en el 
2012, la proporción de casos TB-MDR y examinar los factores clínicos 
y demográficos que se asociaban con este diagnóstico.
Método: Un estudio retrospectivo de cohortes a partir de los datos 
del Registro Nacional Informatizado de Tuberculosis.
Resultados: De los 5377 casos de TB registrados, 2960 
correspondían a SN-PTB (55%). De estos pacientes, 1639 presentaron 
un cultivo positivo (55%) y en 768 casos se diagnosticó TB-MDR 
(47%). De los pacientes con diagnóstico de TB-MDR, el 33% 
correspondió a casos nuevos (363/1084) y el 73% consistió en 
pacientes previamente tratados (405/555). Los factores que se 
asociaron de manera independiente con el diagnóstico de TB-MDR 
fueron el antecedente de tratamiento antituberculoso, la edad, el 
domicilio en zona urbana, la situación frente al virus de la 
inmunodeficiencia humana y el hecho de ser jubilado.
Conclusión: Cerca de la mitad de los pacientes con SN-PTB presentó 
TB-MDR. Esta proporción llegó a ser siete de cada 10 de los casos en 
retratamiento. Con base en estos resultados, está justificada una 
decisión política a escala nacional de ampliación del uso de las 
pruebas rápidas de diagnóstico molecular de manera universal a 
todos los pacientes con TBP, incluidos los pacientes con SN-PTB. Es 
necesario tomar medidas encaminadas a fomentar la ejecución de 
esta prioridad urgente, dadas las repercusiones que un diagnóstico 
tardío impone a los pacientes y al sistema de salud pública.
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